Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

Summary by AI BETAClose X

Novo Nordisk presented findings from the POSEIDON study at the European Atherosclerosis Society Congress, revealing that two in five people with atherosclerotic cardiovascular disease and chronic kidney disease, or heart failure, exhibit cardiovascular inflammation, measured by hsCRP levels of 2 mg/L or higher. This inflammation, present despite standard care, is an independent risk factor for heart attack and stroke, indicating a significant gap in global cardiovascular care. The study involved 18,904 patients across 18 countries, with 42.7% of ASCVD patients also having CKD, and 11,809 patients having heart failure. These results highlight the persistent inflammatory risk and the potential need for therapies targeting inflammation.

Disclaimer*

UK 100

Latest directors dealings